Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Acceligen is a private animal biotechnology company focused on precision breeding and gene editing in food animals. The company develops and commercializes livestock traits intended to improve animal health, welfare, sustainability, and productivity, primarily in cattle, swine, aquaculture, and dairy systems. Publicly described programs include PRLR-SLICK cattle for heat tolerance and PRRSV-resistant pigs, alongside broader trait-development efforts for disease resilience and productivity. Acceligen operates as a wholly owned subsidiary of Recombinetics and works with reproductive-technology and regional commercialization partners to deploy edited traits into elite breeding lines. Its business is best characterized as agricultural and animal-health biotech rather than human therapeutics.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Acceligen.